Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment

被引:20
|
作者
Bose, Gauruv [1 ,2 ]
Freedman, Mark S. [1 ,2 ]
机构
[1] Ottawa Hosp, Res Inst, Div Neurol, Gen Campus,501 Smyth Rd,Box 601, Ottawa, ON K1H 8L6, Canada
[2] Univ Ottawa, Dept Med, Ottawa, ON, Canada
关键词
Multiple sclerosis; precision medicine; patient-centered care; neurology; STEM-CELL TRANSPLANTATION; DISABILITY PROGRESSION; CLADRIBINE TABLETS; DISEASE; OCRELIZUMAB; ALEMTUZUMAB; PLACEBO; PREDICT; LESIONS; MS;
D O I
10.1177/1352458519887324
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system (CNS), affecting patients of all ages, causing neurologic disability if inadequately treated. Some patients have a relatively benign disease course without significant disability after decades, while a more aggressive course ensues in others and disability progression occurs after only several years. Certain risk factors confer a higher chance of a patient having aggressive MS. Currently over 15 disease-modifying treatments (DMTs) are approved for MS with different efficacy and safety profiles. Deciding which DMT to use in a specific patient requires a careful analysis of a patient's disease course for high-risk factors for early progression, consideration of the efficacy and safety profile for potential therapy, as well as understanding of a patient's lifestyle and expectations. The integration of these factors is the art of precision medicine, a necessary practice in the treatment of patients with MS.
引用
收藏
页码:540 / 547
页数:8
相关论文
共 50 条